JP5957385B2 - 複製タンパク質ａを阻害する物質および方法ならびにその使用 - Google Patents

複製タンパク質ａを阻害する物質および方法ならびにその使用 Download PDF

Info

Publication number
JP5957385B2
JP5957385B2 JP2012552130A JP2012552130A JP5957385B2 JP 5957385 B2 JP5957385 B2 JP 5957385B2 JP 2012552130 A JP2012552130 A JP 2012552130A JP 2012552130 A JP2012552130 A JP 2012552130A JP 5957385 B2 JP5957385 B2 JP 5957385B2
Authority
JP
Japan
Prior art keywords
compound
group
chloro
therapeutic agent
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012552130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518906A (ja
Inventor
トゥルチ，ジョン，ジェィ．
シュック，サラ
Original Assignee
インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション filed Critical インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション
Publication of JP2013518906A publication Critical patent/JP2013518906A/ja
Application granted granted Critical
Publication of JP5957385B2 publication Critical patent/JP5957385B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012552130A 2010-02-05 2011-02-05 複製タンパク質ａを阻害する物質および方法ならびにその使用 Active JP5957385B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30177810P 2010-02-05 2010-02-05
US61/301,778 2010-02-05
PCT/US2011/023838 WO2011097545A1 (en) 2010-02-05 2011-02-05 Materials and method for inhibiting replication protein a and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016051186A Division JP6316859B2 (ja) 2010-02-05 2016-03-15 複製タンパク質ａを阻害する物質および方法ならびにその使用

Publications (2)

Publication Number Publication Date
JP2013518906A JP2013518906A (ja) 2013-05-23
JP5957385B2 true JP5957385B2 (ja) 2016-07-27

Family

ID=44355820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012552130A Active JP5957385B2 (ja) 2010-02-05 2011-02-05 複製タンパク質ａを阻害する物質および方法ならびにその使用
JP2016051186A Active JP6316859B2 (ja) 2010-02-05 2016-03-15 複製タンパク質ａを阻害する物質および方法ならびにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016051186A Active JP6316859B2 (ja) 2010-02-05 2016-03-15 複製タンパク質ａを阻害する物質および方法ならびにその使用

Country Status (6)

Country Link
US (3) US8859532B2 (enExample)
EP (1) EP2531032B1 (enExample)
JP (2) JP5957385B2 (enExample)
BR (1) BR112012019691B1 (enExample)
CA (1) CA2825680C (enExample)
WO (1) WO2011097545A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077752A2 (en) * 2014-11-13 2016-05-19 Indiana University Research And Technology Corporation Materials and method for inhibiting replication protein a and uses thereof
US9897378B2 (en) 2015-10-08 2018-02-20 Nyc Designed Inspirations Llc Cosmetic makeup sponge/blender container
JP6485407B2 (ja) * 2016-06-01 2019-03-20 横河電機株式会社 電磁流量計および誤配線検出方法
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
US11999720B2 (en) 2018-09-19 2024-06-04 The Trustees Of Indiana University Pyrazolylacylpyrazoline compounds and method for treating pain
CN112759614B (zh) * 2019-11-05 2023-03-28 天津医科大学 基于组蛋白去乙酰化酶和复制蛋白a联合靶向的铂类化合物及其制备方法和应用
JP7677646B2 (ja) * 2019-12-10 2025-05-15 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055116A1 (en) * 2006-04-13 2010-03-04 Liou Hsiou-Chi Methods and Compositions for Targeting c-Rel
WO2008045663A2 (en) * 2006-10-06 2008-04-17 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
US8716283B2 (en) * 2007-11-07 2014-05-06 University Of Massachusetts Type III secretion inhibitors, analogs and uses thereof

Also Published As

Publication number Publication date
JP2013518906A (ja) 2013-05-23
EP2531032A4 (en) 2013-09-04
BR112012019691B1 (pt) 2021-09-28
EP2531032B1 (en) 2019-04-10
US20140370121A1 (en) 2014-12-18
JP6316859B2 (ja) 2018-04-25
US9730942B2 (en) 2017-08-15
CA2825680C (en) 2019-12-03
US8859532B2 (en) 2014-10-14
US20170182055A1 (en) 2017-06-29
BR112012019691A2 (pt) 2016-08-09
US20130028989A1 (en) 2013-01-31
WO2011097545A1 (en) 2011-08-11
JP2016164166A (ja) 2016-09-08
US9533969B2 (en) 2017-01-03
EP2531032A1 (en) 2012-12-12
WO2011097545A9 (en) 2011-11-17
CA2825680A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
JP6316859B2 (ja) 複製タンパク質ａを阻害する物質および方法ならびにその使用
CA2953079C (en) Intermittent dosing of mdm2 inhibitor
JP6509386B2 (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
JP2022145800A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
US11312676B2 (en) Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
US20240409544A1 (en) SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS
JP2022539840A (ja) Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ
US10774063B2 (en) Materials and method for inhibiting replication protein A and uses thereof
US10392398B2 (en) Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics
US9802948B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
US20190365745A1 (en) Use of chronic treatment with atr inhibitors to sensitize cancer cells to parp inhibitors
US20180055816A1 (en) Pyranonaphthoquinone compounds and methods of use thereof
Wang et al. Homoharringtonine inhibits pancreatic cancer progression via mitochondrial energy metabolism suppression and macrophages reduction
FR3068971A1 (fr) Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160620

R150 Certificate of patent or registration of utility model

Ref document number: 5957385

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250